Cited by 383SARS-CoV-2 and COVID-19 ResearchT-cell and B-cell ImmunologyImmune responses and vaccinations

The DOI matches its Crossref record; 62 of the 65 references it cites were found in a registry or an index.

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

Open access

Lederer, Katlyn, Castaño, Diana, Gómez Atria, Daniela, Oguin, Thomas H., Wang, Sidney, Manzoni, Tomaz B., Muramatsu, Hiromi, Hogan, Michael J., Amanat, Fatima, Cherubin, Patrick, Lundgreen, Kendall A., Tam, Ying K., Fan, Steven H.Y., Eisenlohr, Laurence C., Maillard, Ivan, Weissman, Drew, Bates, Paul, Krammer, Florian, Sempowski, Gregory D., Pardi, Norbert, Locci, Michela·2020·Immunity

DOI 10.1016/j.immuni.2020.11.009PMC PMC7680029

Open this paper in CoChat — free account Open PDF

Abstract

The deployment of effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to eradicate the coronavirus disease 2019 (COVID-19) pandemic. Many licensed vaccines confer protection by inducing long-lived plasma cells (LLPCs) and memory B cells (MBCs), cell types canonically generated during germinal center (GC) reactions. Here, we directly compared two vaccine platforms-mRNA vaccines and a recombinant protein formulated with an MF59-like adjuvant-looking for their abilities to quantitatively and qualitatively shape SARS-CoV-2-specific primary GC responses over time. We demonstrated that a single immunization with SARS-CoV-2 mRNA, but not with the recombinant protein vaccine, elicited potent SARS-CoV-2-specific GC B and T follicular helper (Tfh) cell responses as well as LLPCs and MBCs. Importantly, GC responses strongly correlated with neutralizing antibody production. mRNA vaccines more efficiently induced key regulators of the Tfh cell program and influenced the functional properties of Tfh cells. Overall, this study identifies SARS-CoV-2 mRNA vaccines as strong candidates for promoting robust GC-derived immune responses.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2020.11.009

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

WHO Declares COVID-19 a Pandemic.
Cucinotta, D., & Vanelli, M. (2020) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v91i1.9397 · Cited by 8,022 · cited 1×
“The coronavirus disease 2019 (COVID-19) outbreak was declared a pandemic in March 2020 (Cucinotta and Vanelli, 2020) and has led to a worldwide health emergency, calling for rapid and efficient countermeasures.”
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 4×
“First, mRNA-encoding SARS-CoV-2 antigens are translated into proteins directly in the host cells (Pardi et al., 2018b), and it was shown for the LucmRNA control vaccine that Luciferase expression is detectable for at least 10 days after injection (Pardi et al.”
InfluentialSelf-citation
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595 · cited 1×
“This finding is in line with recently reported correlations of antigenspecific CD4 T cells (Grifoni et al., 2020) and circulating Tfh cells (Mathew et al.”
Self-citation
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · cited 2×
“…Abs (nAbs) (Laczkó et al., 2020), as well as by similar findings on SARS-CoV-2mRNA vaccine candidates currently in clinical trials (Anderson et al., 2020; Corbett et al., 2020a; 2020b; Jackson et al., 2020; Mulligan et al., 2020a; Sahin et al., 2020; Walsh et al., 2020; Zhang et al., 2020).”
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977 · cited 6×
“The SARS-CoV-2 vaccine field is moving at a fast pace, and several preclinical and clinical studies have been published thus far reporting a limited characterization of the immune responses induced by the SARS-CoV-2 vaccine candidates (Corbett et al., 2020b; 2020a; Gao et al., 2020; Jackson et al., 2020; Laczkó et al.…”
Influential
Interferon-γ and B Cell Stimulatory Factor-1 Reciprocally Regulate Ig Isotype Production
Snapper, C. M., & Paul, W. E. (1987) · Science · doi:10.1126/science.3107127 · Cited by 1,927 · cited 1×
“Conversely, Th1 polarized responses are linked to IgG2 Ab production (Reinhardt et al., 2009; Snapper and Paul, 1987; Stevens et al., 1988).”
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Self-citation
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615 · cited 4×
“…Abs (nAbs) (Laczkó et al., 2020), as well as by similar findings on SARS-CoV-2mRNA vaccine candidates currently in clinical trials (Anderson et al., 2020; Corbett et al., 2020a; 2020b; Jackson et al., 2020; Mulligan et al., 2020a; Sahin et al., 2020; Walsh et al., 2020; Zhang et al., 2020).”
Influential
T follicular helper cell biology: a decade of discovery and diseases
Crotty, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.011 · Cited by 1,591 · cited 10×
“SARS-CoV-2 mRNA Vaccines Are Superior in Comparison to rRBD-AddaVax Vaccine at Inducing SARS-CoV-2-Specific Tfh Cells Tfh cells are key regulators of GC responses (Crotty, 2019; Vinuesa et al., 2016).”
Influential

Show all 65 references

Research works printed but not linked: 1

Mulligan, 2020, Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, Nature, 586, 589, 10.1038/s41586-020-2639-4 · DOI · Paper page

Sorted by citations

Items 301–382 of 382

Waning Humoral Immune Response Following the Third and Fourth SARS‐COV‐2 Vaccine: A Cohort Study in Healthcare Workers
Süner, A. F., Ergör, G., Çağlayan, D., Türe, N., Güzel, I., Irmak, Ç., IŞIK, E., Appak, Ö., Çelik, M., Öztürk, G., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.70003 · Cited by 2
“However, mRNA vaccines specifically stimulate antibody responses strongly [43], although their effects on cellular immunity are not fully resolved [44].”
Polyvalent mRNA vaccine targeting outer surface protein C affords multi-strain protection against Lyme disease
Pfeifle, A., Lansdell, C., Zhang, W., Tamming, L. A., Anderson-Duvall, R., Raman, S. N. T., Gravel, C., Wu, J., Frahm, G. E., Creskey, M., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01326-3 · Cited by 2
“…memory B cells, long-lived plasma cells, and antibody titers than recombinant protein vaccines, including in the context of LD vaccination 46,47,75,76 . crOspC vaccines composed of immunodominant epitopes from diverseOspCtypescanelicitantibodiesthatrecognizemorethan20distinct OspC types and…”
COVID-19 Vaccine-Associated Lymphadenopathy in Breast Imaging Recipients: A Review of Literature
Aleman, R. T., Rauch, J. M., Desai, J., & Chaiban, J. T. (2022) · Cureus · doi:10.7759/cureus.26845 · Cited by 2
The Effect of SARS-CoV-2 Vaccination on B-Cell Phenotype in Systemic Sclerosis Patients
Pellicano, C., Colalillo, A., Basile, V., Marino, M., Basile, U., Gualana, F. L., Mezzaroma, I., Visentini, M., & Rosato, E. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091420 · Cited by 2
“SARS-CoV-2 vaccines are able to induce specific cellular and humoral responses generating immune memory, as activation of B cells plays a key role in the effectiveness of the response to vaccination [4].”
Background
Prediction of effective humoral response to SARS-CoV-2 vaccines in healthy subjects by cortical thickness of post-vaccination reactive lymphadenopathy
Rouilleault, A. C. I., Soriano, I., Quan, P. L., Reina, G., del Pozo, J. L., Gónzalez, Á., Fernández-Ciriza, L., Fernández‐Montero, A., Pina, L., & Elizalde, A. (2023) · European Radiology · doi:10.1007/s00330-023-09662-5 · Cited by 2
“Lymph nodes represent the activation center of the immune response, where vaccine-peptide antigens are presented by APCs to residing lymphocytes in order to elicit two main responses: cellular response, with the formation of cytotoxic T lymphocytes capable of directly killing infected cells, and a humoral response, wh…”
Background
Boosting with Omicron-specific mRNA vaccine or historical SARS-CoV-2 vaccines elicits discriminating immune responses against Omicron variants
Wu, Y., Jia, X., Wu, N., Zhang, X., Wu, Y., Liu, Y., Zhou, M., Shen, Y., Li, E., Wang, W., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.030 · Cited by 2
COVID-19 vaccination and pregnancy-induced hypertension risk in women undergoing assisted reproduction
Ma, S., Zheng, Y., Fang, M., Xiong, Y., Hu, L., Liu, Y., Gong, F., Krämer, B. K., Lin, G., & Hocher, B. (2025) · Human Reproduction · doi:10.1093/humrep/deaf055 · Cited by 2
A recombinant BCG with surface-displayed antigen induces humoral and cellular immune responses
Zhang, J., Hu, Z., Xing, L., Chen, Z., Xu, J., Wu, Q., Wu, J., Zhao, G., Fan, X., & Lyu, L.-D. (2025) · Scientific Reports · doi:10.1038/s41598-025-00553-x · Cited by 3
Dietary supplementation of arachidonic acid promotes humoral immunity
Feng, S., Ma, E., Na, X., Wang, Z., Tai, W., Bao, X., Wang, M., Chang, H., Wu, B., Liu, M.-Y., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00310-7 · Cited by 2
“This enables the production of neutralizing antibodies with high af ﬁ nity (Lederer et al, 2022; Lederer et al, 2020; Sharma et al, 2024; Victora and Nussenzweig, 2022).”
Dynamics of B-Cell Responses after SARS-CoV-2 Vaccination in Spain
José-Cascón, M. S., de la Varga‐Martínez, R., Campos‐Caro, A., & Rodriguez, C. S. (2022) · Vaccines · doi:10.3390/vaccines10101615 · Cited by 2
“This fact can be related to the prolonged germinal centre response documented after SARS-CoV-2 mRNA BNT162b2S vaccination [10,11].”
BackgroundResult
Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination
Dentone, C., Fenoglio, D., Ponzano, M., Cerchiaro, M., Altosole, T., Franciotta, D. M., Portunato, F., Mikulska, M., Taramasso, L., Magnasco, L., et al. (2022) · Vaccines · doi:10.3390/vaccines10111784 · Cited by 2
THE ANTI SARS-COV-2 VACCINES AND THE QUESTIONSTHEY RAISE
Labidi, A. H. (2021) · International Journal of Advanced Research · doi:10.21474/ijar01/12734 · Cited by 2
Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model
Jiang, S., Wu, S., Zhao, G., He, Y., Bao, L., Liu, J., Qin, C., Hou, J., Ding, Y., Cheng, A., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2016201 · Cited by 2
Directing an mRNA-LNP vaccine toward lymph nodes improves humoral and cellular immunity against SARS-CoV-2Preprint
Francis, D. M., Chen, R., Khorsandzadeh, S., Hu, Q., Lyu, X., Wang, H., Lim, W.-L., Sun, H., Xie, H., Shaabani, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.25.457699 · Cited by 2
Immunogenicity of SARS-CoV-2 trimetric spike protein associated to Poly(I:C) plus AlumPreprint
dos-Santos, J. S., Firmino-Cruz, L., da Fonseca-Martins, A. M., Oliveira-Maciel, D., Pérez, G., Pereira, V. A. R., Dumard, C. H., Guedes-da-Silva, F. H., Santos, A. C. V., Leandro, M. D. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.05.461434 · Cited by 2
A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infectionPreprint
Coria, L. M., Saposnik, L. M., Castro, C. P., Castro, E. F., Bruno, L. A., Stone, W. B., Pérez, P. S., Darriba, M. L., Chemes, L. B., Alcaín, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.07.471590 · Cited by 2
A broadly protective CHO cell expressed recombinant spike protein subunit vaccine (IMT-CVAX) against SARS-CoV-2Preprint
Jitender, Kumar, B. V., Singh, S., Verma, G., Kumar, R., Mishra, P. M., Kumar, S., Nagaraj, S. K., Nag, J., Joy, C. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.03.534161 · Cited by 2
Epidemiology of Immune-Mediated Glomerulopathies before and after SARS-CoV-2 Vaccination: A Tertiary Referral Hospital Experience
Zamora, J. I., López-Martínez, M., Patricio-Liébana, M., León-Román, J. C., Bermejo, S., Vergara, A., Agraz, I., Ramos-Terrades, N., Azancot, M. A., Toapanta, N., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062420 · Cited by 1
“Interestingly, it has been postulated that, in contrast with live virus vaccines and natural infection, mRNA vaccines produce higher antibody titers and more potent CD4+, CD8+, and T follicular helper B cell (TFH) responses [13].”
Background
Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand
Temchura, V., Wagner, J. T., & Damm, D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010024 · Cited by 3
Distinguishing Axillary Lymphadenopathy after COVID-19 Vaccination from Malignant Lymphadenopathy
Yamanaka, S., Tanaka, K., Miyagawa, M., Kido, T., Hasebe, S., Yamamoto, S., Fujii, T., Takeuchi, K., & Yakushijin, Y. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123387 · Cited by 1
“…of lymphadenopathy on various imaging modalities, including ultrasonography (US), CT, MRI, and 18F-FDG PET, has been documented in several case reports and small cohort studies, and the incidence [7–14] and the immunological mechanisms behind its development [15–17] are currently being clarified.”
Background
A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets
Hashimoto, M., Tsujii, K., Nakajima-Yoshida, H., Akiyama, N., Yoshihara, K., Dohi, K., Yin, Z., Ejima, A., Yamamoto-Mizuno, S., Nojiri, Y., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126780 · Cited by 1
Increased STAT3 Phosphorylation in CD4+ T-Cells of Treated Patients with Chronic Lymphocytic Leukemia and Changes in Circulating Regulatory T-Cell Subsets Relative to Tumor Mass Distribution Value and Disease Duration
Dreisinger, M., Roškar, Z., Goropevšek, A., Zakelšek, A., Čurič, S., Živko, N., Bevc, S., & Homšak, E. (2025) · Biomedicines · doi:10.3390/biomedicines13051204 · Cited by 2
“…recent studies in animal models of SARS-CoV-2 and after vaccination against other viral pathogens in humans have shown that the detection of activated CD38 + Tfh-like cells in peripheral blood at an appropriate early time window can predict a subsequent effective antibody response [39,40].”
Harnessing mRNA technology against Fasciola hepatica: Immunological insights from a fatty acid binding protein vaccine
Sánchez‐Montejo, J., Teodósio, C., Strilets, T., López‐Abán, J., Manzano-Román, R., Pozo, J., Martín, S., Silos, L., Trujillo-Rodríguez, I., García-Blanco, M. A., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1693674 · Cited by 2
“These results are similar to those of other mRNA vaccines, which enhance antigen-speci ﬁ c responses and stimulate the activation of germinal centers, ultimately leading to the production of neutralizing antibodies against viruses (47).”
17,18-epoxyeicosatetraenoic acid ameliorates mRNA-LNP–induced local inflammation by inhibiting neutrophil infiltration
Iemitsu, K., Yoshii, K., Hirayama, Y., Liu, Z., Hifumi, S., Kondo, S., Ishida, K., Nagatake, T., & Kunisawa, J. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100956 · Cited by 1
“Because LNPs function as adjuvants and enhance immunogenicity (11, 12, 18), we investigated whether 17,18-EpETE would affect vaccine efficacy by measuring antigen-specific antibody production.”
Alternative antigen retention by a gp96-fusion approach induces long-lasting and broad immunity in mice
Cheng, F., Wang, B., Zhu, X., Wang, Z., Wang, H., Li, R., Xing, C., Ju, Y., Wei, R., Li, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67092-x · Cited by 1
“T follicular helper (Tfh) cells can provide the second signal for activating GC B cells by secreting corresponding cytokines 7 .”
Nanoparticle Immunoadjuvant Complexes Augment Germinal Center Responses to Vaccination
Tursi, N. J., Agostino, C. J., Huang, J., Kannan, T., Laenger, N., Londregan, J., Lederer, K., Helble, M., Bedanova, N. M., Livingston, C., et al. (2026) · Advanced Science · doi:10.1002/advs.202517556 · Cited by 1
“Vaccine platforms that generate robust GC responses, such as lipid nanoparticle-formulated mRNA, display altered GC kinetics with B cell responses peaking 7-days post immunization [ 69, 70 ].”
Self-citation
The dual-adjuvant logic of mRNA vaccines
Malewana, G. B. R., & Corbett, K. S. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.01.012 · Cited by 1
Porcine Parvovirus virus-like particle vaccine induces long-term humoral immunity by recruiting T follicular helper and germinal center B cell responses
Hao, C., Ma, Z., Li, J. Q., Qiao, X., Chen, M., Wang, J., Li, Y., Yao, B., Zhang, J. X., Yang, Q., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1817304 · Cited by 1
Innate immune responses underlying local and systemic adverse reactions to mRNA–lipid nanoparticle vaccines
Takano, T., Matsumura, T., & Takahashi, Y. (2026) · International Immunology · doi:10.1093/intimm/dxag040 · Cited by 1
Virological Correlates of IgM–IgG Patterns of Response to SARS-CoV-2 Infection According to Targeted Antigens
Barreiro, P., Candel, F. J., Sanz, J. C., Román, J. S., Carretero, M. D. M., Pérez-Abeledo, M., Ramos, B., Viñuela-Prieto, J. M., Canora, J., Martínez-Peromingo, F. J., et al. (2021) · Viruses · doi:10.3390/v13050874 · Cited by 1
Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy on 18F-fluorodeoxyglucose PET/CT between virus-vector vaccine and mRNA vaccine
Chiang, M., Wang, J., Lin, W., Yen, R., Huang, J.-Y., & Lu, C. (2023) · European journal of medical research · doi:10.1186/s40001-023-01456-1 · Cited by 1
“Lederer et al. reported that the humoral response was stronger with the mRNA vaccine than with the recombinant protein vaccine [37].”
Background
Choice of adjuvant and antigen composition alters the immunogenic profile of a SARS-CoV-2 subunit vaccine
Lykins, W. R., Pollet, J. B. K., White, J. A., Keegan, B. P., Versteeg, L., Strych, U., Chen, W., Mohamath, R., Ramer-Denisoff, G., Reed, S., et al. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1342518 · Cited by 1
Bioproduction and immunogenic evaluation of SARS-CoV-2 prototype vaccine in silkworm BmN cells
Zheng, H., Zhao, H., Xiong, H., Awais, M. M., Zeng, S., & Sun, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134027 · Cited by 1
Individuals carrying the HLA-B*15 allele exhibit favorable responses to COVID-19 vaccines but are more susceptible to Omicron BA.5.2 and XBB.1.16 infection
Meng, L., Pan, Y., Liu, Y., He, R., Sun, Y., Wang, C., Fei, L., Zhu, A., Wang, Z., An, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440819 · Cited by 1
Immunologisch relevante Aspekte der neuen COVID-19-Impfstoffe
Untersmayr, E., Förster‐Waldl, E., Bonelli, M. M., Boztuǧ, K., Brunner, P. M., Eiwegger, T., Eller, K., Göschl, L., Grabmeier‐Pfistershammer, K., Hötzenecker, W., et al. (2021) · Allergo Journal · doi:10.1007/s15007-021-4848-z · Cited by 1
“Durch eine zweite Teilimpfung konnte ein Anstieg der Anti körper stark angeregt werden [10].”
Novel attempts launched toward universal Sarbecovirus vaccine
Li, H., & Saphire, E. O. (2021) · Cell Research · doi:10.1038/s41422-021-00556-z · Cited by 1
Temporal profiling of CD4 T-cell activation and differentiation upon SARS-CoV-2 spike protein immunisationPreprint
Almeida‐Santos, J., Berkachy, R., Tye, C. A., Hassan, J., Kalfaoglu, B., Selkirk, M. E., & Ono, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.21.500987 · Cited by 1
“SARS-CoV-2 vaccines can induce antigen-reactive Tfh cells, contributing to the quality of neutralising antibodies (45).”
BackgroundMethod
Protein-based RBD-C-tag COVID-19 Vaccination Candidate Elicits Protection Activity against SARS-COV-2 Variant InfectionPreprint
Subramani, J., Shaabani, N., Shetty, D., Wu, H., Kwon, S., Li, W., Yue, C., Lahtz, C., Ramirez-Torres, A., Zhou, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.17.456704
State-of-the-art preclinical evaluation of COVID-19 vaccine candidates
Ghosh, D., Bai, B., Ji, Q., Palliyil, S., Yang, G., Kumar, A., & Saxena, A. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00030
“An effective COVID-19 vaccine must trigger a robust serum antibody response against RBD and a complete seroconversion [23-45, 54, 66].”
BackgroundInfluential
ChAdOx1 nCoV-19, BNT162b2 and CoronaVac Vaccines Do Not Induce as Strong Neutralising Antibodies with Broad Variant Protection as Infection and Suggest Vaccines that Induce Broader Sterilising Immunity are Essential to Stop the PandemicPreprint
Chua, J. X., Durrant, L. G., Chok, Y. L., & Lai, O. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4062765
GM-CSF-activated human dendritic cells promote type1 T follicular helper cells (Tfh1) polarization in a CD40-dependent mannerPreprint
Korniotis, S., Saichi, M., Trichot, C., Hoffmann, C., Amblard, E., Viguier, A., Grondin, S., Noël, F., Mattoo, H., & Soumelis, V. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.28.489850
LES VACCINS anti-SARS-Cov-2 et LES QUESTIONS QU'ILS EVOQUENTPreprint
Labdi, A. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/4x763
Intranasal Inoculation of IFN-Lambda Improves SARS-CoV-2-Caused Lung Damage Via Inducing Rapid Viral Clearance and Transcriptional Shift of Lung MacrophagePreprint
Shin, H., Kim, S.-J., Jo, A., Won, J., Gil, C. H., Yoon, S. Y., Cha, H., & Kim, H. J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4143694
Unilateral axillary lymph node fluorodeoxyglucose uptakes after coronavirus disease 2019 vaccination.
Chikasue, T., Kurata, S., Sumi, A., Matsuda, A., Tsubaki, F., Fujimoto, K., & Abe, T. (2022) · PubMed Central · doi:10.22038/aojnmb.2021.59883.1419
Relapse of Monoclonal Gammopathy of Renal Significance after mRNA COVID-19 Vaccination: A Case Report
Tsaftaridis, N., Potoupni, V., Koraka, L., Iatridi, F., Λιούλιος, Γ., Christodoulou, M., Moysidou, E., Stai, S., Fylaktou, A., Papagianni, A. E., et al. (2023) · Life · doi:10.3390/life13030734
“As with any new medical intervention, complications following their administration are sometimes observed, some of them being rare and only in specific populations [6,7].”
BackgroundInfluential
Data from Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections
Azeem, M. I., Nooka, A. K., Shanmugasundaram, U., Cheedarla, N., Potdar, S. V., Manalo, R. J., Moreno, A., Switchenko, J. M., Cheedarla, S., Doxie, D. B., et al. (2023) · doi:10.1158/2643-3230.c.6551220
COVID-19 vaccine induced t-cell immunity influenced by age and comorbidities
Cheepsattayakorn, A., Cheepsattayakorn, R., & Siriwanarangsun, P. (2023) · Journal of Human Virology & Retrovirology · doi:10.15406/jhvrv.2023.10.00263
Immunosuppressive therapy selectively modulates B‐cell responses in patients with rheumatic and musculoskeletal diseases receiving the inactivated COVID‐19 vaccine
Li, R. Q., Guo, R., Li, J., Zheng, B., Xu, R., Jiang, X., Chen, Y., Tang, G. H., Li, Q., Li, Y., et al. (2023) · Rheumatology & autoimmunity · doi:10.1002/rai2.12076
Coronavirus disease 2019 (COVID-19) vaccination-induced unilateral axillary lymphadenopathy: case series with follow-up and literature review
Kim, J., & Ko, S. Y. (2023) · Journal of Medicine and Life Science · doi:10.22730/jmls.2023.20.2.73
Identificação de peptídeos-alvo de anticorpos contra a proteína RBD do vírus SARS-CoV-2 em indivíduos convalescentes e vacinados
de Oliveira, J. R. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-24082023-110203
Development of a single-chain variable antibody fragment against a conserved region of the SARS-CoV-2 spike protein
Gao, T., Irie, A., Kouwaki, T., & Oshiumi, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-64103-7
Immune Responses to mRNA Vaccine
Exposito, J., Monge, C., Arruda, D. C., & Verrier, B. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch2
COVID-19: The vaccine development strategies
Yan, Z., Yang, M., & Lai, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00036-x
Expression, purification and immunogenicity analyses of receptor binding domain protein of severe acute respiratory syndrome coronavirus 2 from delta variant.
Liu, L., Chen, H., Liu, P., Xiao, K., Song, J., Fāng, Y., Kong, L., & Xin, X. L. (2024) · PubMed Central · doi:10.30466/vrf.2024.2013858.4037
“20 The immunogenicity of RBD monomers is suboptimal, and multimeric display of RBD molecules is a potential strategy for the optimization.”
Relapse Risk in Patients with Membranous Nephropathy after Inactivated COVID-19 Vaccination
Zhang, H., Chen, R., Xu, M., Huang, X., Zhao, W., Zhou, J., Zhang, M., Xu, Y., Shang, D., Xie, Q., et al. (2025) · The Nephron journals/Nephron journals · doi:10.1159/000544754
“Studies have shown that vaccines can stimulate strong antigen-speci ﬁ c T-cell responses, including T follicular helper cells, and potent germinal center B-cell responses, leading to sustained production of neutralizing antibodies [14].”
Evaluating the impact of COVID-19 infection and vaccination on the presentation and severity of idiopathic granulomatous mastitis: A retrospective cohort study
ERKAN, S., Aytac, H. O., Ozdemir, H., Avcı, T., GÜNDOĞDU, R., Kus, M. M., Güneşli, A., Pehlivan, U. A., & Yalçın, Ç. (2025) · Medicine · doi:10.1097/md.0000000000043151
“[27] Approximately 0.3% of individuals receiving the Pfizer-BioNTech vaccine were reported to have lymphadenopathy, compared to 0.1% in the placebo group.”
Influential
Development Of mRNA Vaccines And Therapeutics Beyond Covid-19
Yadav, A., Dwivedi, A., & Darwhekar, G. N. (2025) · European journal of parenteral & pharmaceutical sciences · doi:10.37521/ejpps30211
Why it takes 2 shots to make mRNA vaccines do their antibody-creating best – and what the data shows on delaying the booster dose
Petri, W. A. (2021) · doi:10.64628/aai.mc55cswkf
¿Cuánto nos va a durar la inmunidad frente al coronavirus?
Infantas, I. (2021) · doi:10.64628/aao.x7569ry7y
Longitudinal T- and B-cell recall response after vaccination with Pfizer-BioNTech mRNA vaccine BNT162b2
El-Orfali, Y., Mansour, R., Alkalamouni, H., Jabbour, Z. C., Fayad, A. G. A., Saba, E. S., Khawaja, G., & Massaad, M. J. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.10.001 · Cited by 1
T Cell Dysfunction in HIV Infection and Its Therapeutic Prospects
王, 宣. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15103003
Autoantigen Peptide‐8‐Arm Polyethylene Glycol‐Dyes Specifically Recognize Antigen‐Specific B Cells and Improve the Diagnosis of Rheumatoid Arthritis
Liu, S., Shi, C., Cao, L., Huang, J., Xie, Y., Wei, C., Xiong, Y., Shen, B., Cai, X., Li, T., et al. (2025) · Arthritis & Rheumatology · doi:10.1002/art.70003
Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naïve and convalescent populations
Abbad, A., Lerman, B., Ehrenhaus, J., Ojeda, D. S., Gleason, C., Singh, G., Khalil, Z., Gonzalez-Reiche, A. S., Srivastava, K., Fernández-Sesma, A., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128018
Self-citation
Pre-vaccine immune profiling in cancer patients identifies correlates of COVID-19 vaccine responses
Pasikhani, M. K., Mahov, S., Foley, J., Merin, N. M., Choi, S. Y., Lownik, J. C., Xu, A. M., Milshteyn, L., Villamejor, A. L., Nadri, M., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2599622
“5,7 11–14 Apart from adaptive immune responses, COVID-19 vaccination provides additional protection by stimulating monocytes and natural killer (NK) cells from the innate immune compartment.”
Humoral epitope dominance and immune imprinting by SARS ‐ CoV ‐1 and SARS ‐ CoV ‐2 vaccines
Burnett, D. L., Moxon, A., Aggarwal, A., Jackson, K., Cotter, C. A., Akerman, A., Russell, A. J., KALMAN, R., Langley, D. B., Henry, J. Y., et al. (2026) · Immunology and Cell Biology · doi:10.1111/imcb.70072
CD25 modulation enhances broadly neutralizing antibody response of SARS-CoV-2 subunit vaccine
Li, F., Yu, X., Zhang, C., Liu, W., Tian, H., Wang, X., Wang, P., Yu, B., & Yu, X. (2026) · Communications Biology · doi:10.1038/s42003-026-09721-9
Sex differences in vaccine-induced immunity in mice immunized with integrase-defective lentiviral vector delivering the SARS-CoV-2 Spike protein
Farina, I., Gallinaro, A., Borghi, M., Pirillo, M. F., Falce, C., Canitano, A., Michelini, Z., Zappitelli, A., Virgilio, A. D., Picozza, M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1778067
Heterologous RBMRNA-405 mRNA booster enhances humoral immunity post-inactivated COVID-19 vaccination: a randomized clinical trial in adults and older through 12 months
Yong, X., He, J., Zhang, C., Wang, Y., Ou, Y., & Zhang, B. (2026) · Scientific Reports · doi:10.1038/s41598-026-45429-w
Rôle des lymphocytes T CD4+ folliculaires dans la physiopathologie de la leucémie lymphoïde chronique
Saos-Patrinos, C. L. (2022) · theses.fr (ABES) · doi:10.70675/4f453e7ez711dz4d69zb6a7za6180588786a
Prise en charge d’une infection virale chronique (BK polyomavirus) et d’une infection virale aigue (SARS-CoV-2) dans une population de transplantés rénaux
Benotmane, I. (2022) · theses.fr (ABES) · doi:10.70675/455fe577zd380z46f6z814dz93269a8eb96b
Broadly neutralizing monoclonal antibodies derived from mRNA LNP immunization exhibit potent neutralizing ability against JN.1, KP.3.1.1 and XEC new Omicron variants
Chiang, H.-L., Lin, H.-T., Chen, W.-Y., Liang, K.-H., Lu, R., & Wu, H. (2026) · Journal of General Virology · doi:10.1099/jgv.0.002251
“Two studies in mice have shown that germinal centre responses and SHM are initiated rapidly following mRNA vaccination, typically within 1–2 weeks after immunization [34, 35], suggesting that early affinity maturation occurs within a relatively short time frame.”
A bivalent mRNA–LNP vaccine confers broad-spectrum protection against both homologous and heterologous H5/H7 highly pathogenic avian influenza viruses in SPF chickens
Wei, D., Pan, Y., Zhang, X., Quan, Y., Feng, S., Huang, M., Sun, L., Yang, Y., Zhou, J. M., Han, X., et al. (2026) · Veterinary Research · doi:10.1186/s13567-026-01790-2
“This regulatory loop ensures that the inflammatory response This finely tuned innate immune activation, coupled with the expression of T helper cytokines such as IL-21, facilitates the formation of germinal centers (GCs) and the subsequent production of high-affinity antibodies [38, 42, 43].”
Bacterial mRNA Vaccines: Programming Immunity Against Antimicrobial Resistance
Liao, R., Mingxing, L., Yang, F., Xu, L., Zhang, J., Zhang, W., Guan, S., Zhang, Y. M., Luo, P., Cheng, P., et al. (2026) · Drug Development Research · doi:10.1002/ddr.70335 · Cited by 1
“Importantly, a subset of germinal center B cells develops into long‐lived memory B cells and bone marrow plasma cells, ensuring durable antibody production (Crotty 2019; Pardi et al. 2018b; Lederer et al. 2020).”
BPTF is essential for vaccine-induced germinal center B cell responses
Sturtz, A. J., Evavold, B. K., Rarani, Z. H., Alsoussi, W. B., Zhou, J. Q., Matz, H. C., Muramatsu, H., Simkins, W., Malladi, S. K., McIntire, K. M., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag126
Self-citation
Artificial intelligence-assisted drug designing, toxicity assessment, and biodelivery
Mitra, P., Bhaduri, S., Das, D., & Haldar, D. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43934-6.00032-8
The Role of CD4 T Cell Repertoire and Immune Memory Mechanisms in Vaccination and Infection Immunity
Masato, K. U. B. O. (2026) · Immunological Reviews · doi:10.1111/imr.70148
Experimental evidence and consequences of biomolecular corona formation on inhaled mRNA lipid nanoparticles
Guérin, M., Saorin, A., & Martinez‐Serra, A. (2026) · Health Nanotechnology · doi:10.1186/s44301-026-00036-6 · Cited by 2
“Germinal-center analyses of SARS-CoV-2 mRNA vaccination clarified how mRNA platforms can sustain adaptive immune maturation [178].”
Impact of COVID-19 Vaccination on Patients with Non-Small Cell Lung Cancer Receiving First-Line Immune Checkpoint Inhibitor Therapy: Real-World Evidence from Romania
Gheorghiţă, V., Cotan, H. T., Pistol, A., Orlov-Slavu, C. M., Tianu, E., Lazar, A. T., Stanciu, M., Radoi, I., Mitroi, L., & Niţipir, C. (2026) · Medicina · doi:10.3390/medicina62081588
“Adenoviral vector vaccines (Vaxzevria ® , Janssen) stimulate innate immunity primarily via DNA sensing and vector-induced inflammation, generally eliciting a qualitatively different and less intense IFN-I response [19,20].”
Hyperactive STAT1 promotes Tfh1-cell differentiation to trigger autoimmunity
Chen, R., Chen, X., Yang, J., Mu, H., Mao, S., Chen, S., Gan, R., Wei, Q., Tang, W., Wu, J., et al. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.08.030
Phenotypic and functional characterization of porcine T follicular helper and regulatory cells
Zaki, D., Schmidt, S., Wells, J., Borrow, P., Gerner, W., Graham, S. P., & Edwards, J. C. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag264
Bioengineering strategies for improving the immunogenicity of mRNA vaccines
Wang, H., Zhuo, R., Wu, J., & Ouyang, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02991-z
“15,16 As the ﬁ eld expands beyond acute viral respiratory pathogens, mRNA vaccine development increasingly faces indication-speci ﬁ c demands that are not adequately addressed by current one-size-ﬁ ts-all formulations.”
Intramuscular non-replicating Tiantan vaccinia drives antibody maturation and sterilizing protection against orthopoxvirus in mice
Wang, Y., Wu, C., Huang, B., Huo, S., Huang, J., Ma, J., Jiang, Y., Jin, L., Liu, S., Wang, W., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.10.008

Authors: Lederer, K., Castaño, D., Gómez Atria, D., Oguin, T. H., Wang, S., Manzoni, T. B., Muramatsu, H., Hogan, M. J., Amanat, F., Cherubin, P., Lundgreen, K. A., Tam, Y. K., Fan, S. H. Y., Eisenlohr, L. C., Maillard, I., Weissman, D., Bates, P., Krammer, F., Sempowski, G. D., Pardi, N., & Locci, M.
Affiliations: University of Pennsylvania (US)
Universidad de Antioquia (CO)
Duke University (US)
Children's Hospital of Philadelphia (US)
Icahn School of Medicine at Mount Sinai (US)
Acuitas Therapeutics (Canada) (CA)
Corresponding author: Locci, Michela
ORCID: Lederer, Katlyn
Castaño, Diana
Oguin, Thomas H.
Wang, Sidney
Manzoni, Tomaz B.
Muramatsu, Hiromi
Amanat, Fatima
Lundgreen, Kendall A.
Tam, Ying K.
Eisenlohr, Laurence C.
Maillard, Ivan
Weissman, Drew
Bates, Paul
Krammer, Florian
Sempowski, Gregory D.
Pardi, Norbert
Locci, Michela
Venue: Immunity
Publisher: Elsevier BV
Published: 2020-12
Volume: 53
Issue: 6
Pages: 1281-1295.e5
ISSN: 1074-7613 (ISSN-L)
DOI: 10.1016/j.immuni.2020.11.009
PMC: PMC7680029
OpenAlex: W3109969518
Cited by: 383
References: 65
Citations by year: 2026: 27 · 2025: 39 · 2024: 50 · 2023: 61 · 2022: 97 · 2021: 105 · 2020: 4
FWCI: 8.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 379 d)
Locations: Immunity (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Institutional Repository University of Antioquia (University of Antioquia) (publishedVersion, cc-by-nc-nd)
Funders: National Institutes of Health
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Keywords: SARS-CoV-2, COVID-19 vaccines, mRNA vaccines, recombinant protein vaccine, MF59 adjuvant, germinal center reaction, T follicular helper cells, long-lived plasma cells, memory B cells, neutralizing antibodies, B cell response, vaccine platform comparison
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, Epitopes, Antigens, Viral, B-Lymphocytes, Cells, Cultured, T-Lymphocytes, Helper-Inducer, Humans, Lymphocyte Activation, Polysorbates, Recombinant Proteins, RNA, Viral, Squalene, Vaccination, Vaccines, Synthetic, Germinal Center, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks